Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Rajeev Ayyagari"'
Autor:
Eric D. Whitman, Todor I. Totev, Shan Jiang, Wilson L. da Costa, Dmitri Grebennik, Hongjue Wang, Andra-Ecaterina Boca, Rajeev Ayyagari
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background The objective of this study was to describe real-world adjuvant therapy (AT) use by disease substage and assess determinants of treatment choice among patients with stage III melanoma. Methods This non-interventional retrospective
Externí odkaz:
https://doaj.org/article/553c3a36eefb4e3e9989381e0ef920bc
Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract Background Tardive dyskinesia (TD) has a multidimensional impact on patients with TD and, as importantly, their caregivers. An online survey was developed and administered to assess patient and caregiver burden of TD. Survey participants wer
Externí odkaz:
https://doaj.org/article/617abd7396854f549223f4e3a6205aad
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/5b5572520d82440d8c2de9565992b226
Autor:
Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Background Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy and safety of fremane
Externí odkaz:
https://doaj.org/article/459b359bd0684724bbb509f6d2b6cb05
Autor:
Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-15 (2022)
Abstract Background The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, hav
Externí odkaz:
https://doaj.org/article/12dd913a8637410284ba9557236c8ce7
Autor:
Meredith E. Mowitz, Wei Gao, Heather Sipsma, Pete Zuckerman, Hallee Wong, Rajeev Ayyagari, Sujata P. Sarda
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 9, Iss 2 (2022)
**Background:** The effect of gestational age (GA) on comorbidity prevalence, healthcare resource utilization (HCRU), and all-cause costs is significant for extremely premature (EP) infants in the United States. **Objectives:** To characterize real-
Externí odkaz:
https://doaj.org/article/5b6087529101443d94c8a9b86c3c2cbd
Publikováno v:
BMC Psychiatry, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background The relative benefits and risks of long-term maintenance treatment with antipsychotics have not been well studied in patients with bipolar disorder and major depressive disorder. For example, while antipsychotic dose reduction has
Externí odkaz:
https://doaj.org/article/036d659fd5b141b58c8973ea0f23e0e3
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Tardive dyskinesia (TD) is a serious, often irreversible movement disorder caused by prolonged exposure to antipsychotics; identifying patients at risk for TD is critical to preventing it. Predictive models for the occurrence of T
Externí odkaz:
https://doaj.org/article/ec9cf544fde3440ca6b18cfd8a756a7c
Autor:
Lieneke F.M. Ariëns, Abhijit Gadkari, Harmieke van Os-Medendorp, Rajeev Ayyagari, Emi Terasawa, Andreas Kuznik, Zhen Chen, Gaëlle Bégo-Le Bagousse, Yufang Lu, Elena Rizova, Neil M.H. Graham, Gianluca Pirozzi, Marjolein De Bruin-Weller, Laurent Eckert
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 10, Pp 851-857 (2019)
Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for
Externí odkaz:
https://doaj.org/article/cb9d787cf6bd4596bf1c42e03864f80f
Publikováno v:
BMC Psychiatry, Vol 18, Iss 1, Pp 1-13 (2018)
Abstract Background Data are limited on the benefits and risks of dose reduction in managing side effects associated with antipsychotic treatment. As an example, antipsychotic dose reduction has been recommended in the management of tardive dyskinesi
Externí odkaz:
https://doaj.org/article/04b9774998494e9b9f9b83570a445680